Do you want to read an article? Please log in or register.
TP53-associated early breast cancer: new observations from a large cohort
Breast Cancer
Related content
RECOMMENDED
Breast Cancer
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Eur J Cancer
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G
doi: 10.1016/j.ejca.2024.113535
Breast Cancer
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer
JAMA Oncol
O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell'Orto P, Lang I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, Müller B, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM
doi: 10.1001/jamaoncol.2024.3044
Breast Cancer
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
Lancet Oncol
Williams LJ, Kunkler IH, Taylor KJ, Dunlop J, Piper T, Caldwell J, Jack W, Loane JF, Elder K, Bartlett JMS, Dixon JM, Cameron DA
doi: 10.1016/S1470-2045(24)00347-4
RECOMMENDED
Breast Cancer
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
★ 3
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Meattini I, De Santis MC, Visani L, Scorsetti M, Fozza A, Meduri B, De Rose F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino G, Moscetti L, Colciago RR, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-Person O, Lambertini M, Marrazzo L, Saieva C, Spanic T, Strnad V, Wheelwright S, Poortmans PMP, Livi L, EUROPA Trial Investigators
doi: 10.1016/S1470-2045(24)00661-2
Breast Cancer
Second Primary Breast Cancer in Young Breast Cancer Survivors
JAMA Oncol
Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Warner E, Come SE, Zheng Y, Kirkner GJ, Snow C, Winer EP, Partridge AH
doi: 10.1001/jamaoncol.2024.0286
SABCS 2024
Breast Cancer
OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer
Breast Cancer
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidance for the prevention of breast cancer-related arm lymphoedema (BCRAL): international Delphi consensus-based recommendations
EClinicalMedicine
Wong HCY, Wallen MP, Chan AW, Dick N, Bonomo P, Bareham M, Wolf JR, van den Hurk C, Fitch M, Chow E, Chan RJ, MASCC BCRAL Expert Panel and the Oncodermatology and Survivorship Study Groups
doi: 10.1016/j.eclinm.2024.102441
Gynecologic Cancer
Prognostic Value of Pre-treatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
Cancer Epidemiol Biomarkers Prev
Andersen HH, Bojesen SE, Johansen JS, Ejlertsen B, Berg T, Tuxen M, Madsen K, Danø H, Flyger H, Jensen MB, Nielsen DL
doi: 10.1158/1055-9965.EPI-23-1299
ASCO 2024
Breast Cancer